myelodysplastic syndromes (MDS) | Page 115 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Perceptions of Disease State, Treatment Outcomes, and Prognosis Among Patients with Myelodysplastic Syndromes: Results From an Internet-Based Survey.

Author(s): 
Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R
Primary Author: 
Sekeres MA
Journal Title: 
Oncologist
Original Publication Date: 
Apr 2011

Bone Marrow Diseases: 

Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: Improved outcomes for de novo disease.

Author(s): 
Andolina JR, Kletzel M, Tse WT, Jacobsohn DA, Duerst RE, Schneiderman J, Helenowski I, Rademaker A, Chaudhury S
Primary Author: 
Andolina JR
Journal Title: 
Pediatr Transplant
Original Publication Date: 
Feb 2011

Allogeneic hematopoetic stem cell transplantation in pediatric

Bone Marrow Diseases: 

Predicted costs of iron-chelators in myelodysplastic syndromes: A 10-year analysis based on actual prevalence and red cell transfusion rates.

Author(s): 
Durairaj S, Chew S, Hyslop A, Keenan N, Groves MJ, Tauro S.
Primary Author: 
Durairaj S
Journal Title: 
Am J Hematol
Original Publication Date: 
May 2011

Consideration of iron-chelation (IC) in transfusion-dependent patients is recommended in most clinical-practice guidelines on myelodysplastic syndromes (MDS). The financial impact of IC on health-care systems is predicted through economic modeling, but an analysis based on actual prevalence is lacking. Here, we have investigated the potential drug-costs and need for IC in a cohort of 189 United Kingdom-based MDS patients diagnosed from 2000 to 2010. Patients with low or intermediate-1 IPSS scores were identified as eligible for IC if ≥24 red

Bone Marrow Diseases: 

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression.

Author(s): 
Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, Hedlund A, Hast R, Schlegelberger B, Porwit A, Hellström-Lindberg E, Mufti GJ.
Primary Author: 
Jädersten M
Journal Title: 
J Clin Oncol
Original Publication Date: 
Apr 2011

PURPOSE To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk

Bone Marrow Diseases: 

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System.

Author(s): 
Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E.
Primary Author: 
Schanz J
Journal Title: 
J Clin Oncol
Original Publication Date: 
Apr 2011

PURPOSE The

Bone Marrow Diseases: 

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms.

Author(s): 
Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegård G, Linder O, Malm C, Markevärn B, Nilsson L, Samuelsson J, Granath F, Landgren O.
Primary Author: 
Björkholm M
Journal Title: 
J Clin Oncol
Original Publication Date: 
May 2011

PURPOSE Patients with myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have a propensity to develop acute myeloid leukemia (AML) and

Bone Marrow Diseases: